{
  "unmetNeeds": [
    {
      "id": "UNMET001",
      "category": "Resistance Mechanism",
      "title": "EGFR T790M Resistance after 3rd-gen TKI",
      "description": "After osimertinib failure, C797S mutation emerges with no approved therapy",
      "affectedPatients": "~30% of osimertinib-treated patients",
      "currentGap": "No FDA-approved 4th generation TKI",
      "evidenceCount": 2,
      "priority": "Critical",
      "potentialSolutions": [
        "4th generation TKI (in development)",
        "Combination therapy (TKI + antibody)",
        "Natural compounds (Artemisinin shows promise)"
      ],
      "relatedGenes": ["EGFR"],
      "relatedAlterations": ["C797S", "T790M"],
      "discoveryOpportunity": "üî• CRITICAL: Urgent unmet need with no approved options"
    },
    {
      "id": "UNMET002",
      "category": "Biomarker Gap",
      "title": "ALK G1202R Mutation Detection",
      "description": "Late-emerging resistance mutation poorly detected by standard NGS panels",
      "affectedPatients": "~15% of lorlatinib-resistant patients",
      "currentGap": "Limited diagnostic coverage, tissue biopsy required",
      "evidenceCount": 1,
      "priority": "High",
      "potentialSolutions": [
        "Enhanced liquid biopsy panels",
        "ctDNA monitoring protocols",
        "Novel inhibitors targeting G1202R"
      ],
      "relatedGenes": ["ALK"],
      "relatedAlterations": ["ALK_G1202R"],
      "discoveryOpportunity": "Early detection could enable timely treatment switch"
    },
    {
      "id": "UNMET003",
      "category": "Treatment Sequence",
      "title": "Optimal Sequencing for ALK+ NSCLC",
      "description": "Unclear which 2nd/3rd-gen ALK inhibitor sequence provides best overall survival",
      "affectedPatients": "All ALK+ NSCLC patients",
      "currentGap": "No head-to-head trials comparing sequences",
      "evidenceCount": 0,
      "priority": "High",
      "potentialSolutions": [
        "Real-world evidence analysis",
        "Biomarker-guided sequencing trials",
        "AI-powered treatment planning"
      ],
      "relatedGenes": ["ALK"],
      "relatedAlterations": ["ALK_fusion"],
      "discoveryOpportunity": "AI/ML analysis of existing data could provide guidance"
    },
    {
      "id": "UNMET004",
      "category": "Rare Mutation",
      "title": "EGFR Exon 20 Insertion Mutations",
      "description": "Poor response to standard EGFR TKIs, limited treatment options",
      "affectedPatients": "~10% of EGFR+ NSCLC",
      "currentGap": "Only one approved drug (amivantamab), high cost",
      "evidenceCount": 1,
      "priority": "High",
      "potentialSolutions": [
        "Novel exon20ins-specific inhibitors",
        "Antibody-drug conjugates",
        "Combination immunotherapy strategies"
      ],
      "relatedGenes": ["EGFR"],
      "relatedAlterations": ["EGFR_ex20ins"],
      "discoveryOpportunity": "Underserved patient population, market opportunity"
    },
    {
      "id": "UNMET005",
      "category": "Combination Therapy",
      "title": "EGFR TKI + Natural Compounds Synergy",
      "description": "Preclinical data shows strong synergy (Curcumin, Artemisinin) but no clinical trials",
      "affectedPatients": "All EGFR+ NSCLC patients",
      "currentGap": "No registered clinical trials for herbal compound combinations",
      "evidenceCount": 0,
      "priority": "Medium",
      "potentialSolutions": [
        "Phase I/II trials with curcumin + osimertinib",
        "Artemisinin formulation for cancer (vs. malaria)",
        "Korean traditional medicine integration"
      ],
      "relatedGenes": ["EGFR"],
      "relatedAlterations": ["EGFR_ex19del", "EGFR_L858R", "T790M"],
      "discoveryOpportunity": "‚≠ê INNOVATION: Bridge Western + Eastern medicine"
    }
  ],
  "drugRepurposingOpportunities": [
    {
      "id": "REPURPOSE001",
      "drug": "Metformin",
      "currentIndication": "Type 2 Diabetes",
      "proposedIndication": "EGFR+ NSCLC (adjuvant metabolic therapy)",
      "rationale": "AMPK activation inhibits mTOR, synergizes with EGFR TKIs",
      "preclinicalEvidence": "IC50 ~2-10 mM in A549, H1975 cells",
      "clinicalEvidence": "Retrospective studies show improved PFS in diabetic NSCLC patients on metformin",
      "feasibility": "High (already approved, safe, cheap)",
      "estimatedCost": "Very low ($10-50/month)",
      "trialProposal": "Phase II: Osimertinib + Metformin vs. Osimertinib alone in 1L EGFR+ NSCLC",
      "priority": "High",
      "discoveryInsight": "üî• LOW-HANGING FRUIT: Safe, cheap, existing data"
    },
    {
      "id": "REPURPOSE002",
      "drug": "Aspirin",
      "currentIndication": "Pain, Cardiovascular protection",
      "proposedIndication": "NSCLC prevention (high-risk EGFR carriers)",
      "rationale": "COX-2 inhibition reduces inflammation, may prevent EGFR-driven tumorigenesis",
      "preclinicalEvidence": "Reduced tumor formation in EGFR-mutant mouse models",
      "clinicalEvidence": "Epidemiological data suggests lower NSCLC incidence in aspirin users",
      "feasibility": "Very High",
      "estimatedCost": "Extremely low ($2-5/month)",
      "trialProposal": "Phase III: Aspirin for NSCLC prevention in EGFR mutation carriers (family history)",
      "priority": "Medium",
      "discoveryInsight": "Prevention strategy for high-risk populations"
    },
    {
      "id": "REPURPOSE003",
      "drug": "Chloroquine/Hydroxychloroquine",
      "currentIndication": "Malaria, Autoimmune diseases",
      "proposedIndication": "EGFR TKI resistance (autophagy inhibition)",
      "rationale": "Blocks protective autophagy that helps cancer cells survive TKI stress",
      "preclinicalEvidence": "Synergizes with gefitinib/erlotinib in resistant cell lines",
      "clinicalEvidence": "Limited Phase I/II data, mixed results",
      "feasibility": "Medium (safety concerns at higher doses)",
      "estimatedCost": "Low ($20-100/month)",
      "trialProposal": "Phase II: Osimertinib + Hydroxychloroquine with biomarker-selected patients (high autophagy)",
      "priority": "Medium",
      "discoveryInsight": "Biomarker selection critical for success"
    }
  ],
  "knowledgeGaps": [
    {
      "area": "EGFR ex19del subtypes",
      "description": "Different deletion sizes (15bp vs. 18bp) may respond differently to TKIs",
      "evidenceCount": 0,
      "impact": "Medium",
      "researchNeeded": "Retrospective analysis of deletion size vs. treatment response"
    },
    {
      "area": "ALK G1202R + I1171X compound mutations",
      "description": "No clinical data on dual-resistant mutations",
      "evidenceCount": 0,
      "impact": "High",
      "researchNeeded": "Case series collection, structural modeling"
    },
    {
      "area": "Herbal compound pharmacokinetics",
      "description": "Curcumin/Berberine bioavailability poorly studied in cancer patients",
      "evidenceCount": 0,
      "impact": "High",
      "researchNeeded": "Phase I PK/PD studies"
    },
    {
      "area": "MRD monitoring for EGFR/ALK+ NSCLC",
      "description": "Minimal residual disease detection after surgery or treatment",
      "evidenceCount": 1,
      "impact": "High",
      "researchNeeded": "Prospective ctDNA monitoring trials"
    }
  ],
  "candidateDiscovery": [
    {
      "id": "CANDIDATE001",
      "name": "Artemisinin-Osimertinib Combination",
      "type": "Natural + Synthetic",
      "target": "EGFR T790M resistance",
      "hypothesis": "Artemisinin induces ferroptosis in T790M cells, synergizing with osimertinib",
      "supportingEvidence": [
        "Artemisinin IC50 5-40 ŒºM in H1975 (T790M+) cells",
        "Synergy index 0.3-0.6 (strong synergy) in combination studies",
        "No overlapping toxicity profiles"
      ],
      "developmentPath": "Phase I/II combination trial",
      "novelty": "First natural-synthetic combo targeting ferroptosis + EGFR",
      "patentability": "High (novel combination, formulation IP)",
      "estimatedTimeline": "3-5 years to Phase II data",
      "fundingPotential": "High (government grants, pharma partnerships)",
      "discoveryScore": 9.2,
      "tags": ["Breakthrough", "Natural Product", "Resistance Mechanism"]
    },
    {
      "id": "CANDIDATE002",
      "name": "Ginsenoside Rg3 + Immunotherapy",
      "type": "Traditional Medicine + Immuno-oncology",
      "target": "EGFR+ NSCLC with low PD-L1",
      "hypothesis": "Rg3 enhances NK cell activity, enabling immunotherapy response in EGFR+ patients",
      "supportingEvidence": [
        "Rg3 increases NK cell infiltration in preclinical models",
        "Phase III data in Asia shows survival benefit as adjuvant",
        "EGFR+ NSCLC typically has low PD-L1 and poor immuno response"
      ],
      "developmentPath": "Phase II: Rg3 + PD-1 inhibitor in EGFR+ NSCLC",
      "novelty": "Novel immune priming strategy for cold tumors",
      "patentability": "Medium (composition of matter for combination)",
      "estimatedTimeline": "4-6 years to pivotal trial",
      "fundingPotential": "Very High (Korean gov, pharma interest)",
      "discoveryScore": 8.7,
      "tags": ["Immunotherapy", "Korean Medicine", "Cold Tumors"]
    },
    {
      "id": "CANDIDATE003",
      "name": "Curcumin Nanoformulation + EGFR TKI",
      "type": "Nanomedicine + TKI",
      "target": "Overcoming poor curcumin bioavailability",
      "hypothesis": "Nanoparticle delivery achieves therapeutic curcumin levels, synergizing with TKIs",
      "supportingEvidence": [
        "Nano-curcumin achieves 10-fold higher plasma levels",
        "Strong in vitro synergy with gefitinib/erlotinib",
        "Phase I nano-curcumin safety established"
      ],
      "developmentPath": "Phase I/II dose-finding + efficacy",
      "novelty": "Solves major bioavailability barrier",
      "patentability": "High (nanoformulation IP)",
      "estimatedTimeline": "2-4 years to Phase II",
      "fundingPotential": "High (nanotech + oncology synergy)",
      "discoveryScore": 8.3,
      "tags": ["Nanomedicine", "Bioavailability", "Combination Therapy"]
    }
  ],
  "aiInsights": {
    "topOpportunities": [
      "EGFR T790M resistance remains #1 unmet need",
      "Natural compound + TKI combinations are underexplored",
      "Korean traditional medicine (Ginseng, Hwangryun) has clinical-stage data"
    ],
    "investmentAreas": [
      "4th generation TKI development",
      "Herbal compound clinical trials",
      "Liquid biopsy for resistance monitoring"
    ],
    "collaborationOpportunities": [
      "Academic hospitals (patient recruitment)",
      "Traditional medicine institutes (Korea, China)",
      "Nanotech companies (formulation)"
    ]
  }
}
